文献速递银屑病与炎症性皮肤病

银屑病角质层无创蛋白质组分析反映病理生理通路并可用于药物评估

Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling.
PubMed 文献 · Br J Dermatol · 2017-05-18

该研究通过重复胶带粘贴无创采集银屑病角质层,用质谱和抗体技术定量蛋白质,并与皮损活检比较。质谱鉴定出140个差异表达蛋白,反映表皮分化受扰;Th1/Th17标志物可定量,Th2细胞因子未检出;趋化因子和sICAM1可用于评估治疗缓解并排序三种外用药的已知临床疗效。

要点

  • 银屑病角质层无创蛋白质组可反映表皮分化异常和炎症通路激活。
  • Th1/Th17相关标志物在皮损角质层可定量,Th2细胞因子未检出。
  • CXCL1、CXCL8、CXCL10和sICAM可用于无创评估药物疗效。

核心结论

  • 银屑病角质层蛋白质生物标志物定量可检测关键病理生理机制,并在转化医学中实现无创药物评估。

研究设计与样本

  • 通过重复胶带粘贴采集银屑病角质层,收集非皮损、皮损及赋形剂或药物处理的皮损样本,并与皮损活检蛋白提取物比较。
  • 以卡泊三醇-倍他米松(CB)为参照药物,采用质谱、Western blotting、酶联免疫吸附试验和Luminex技术定量胶带粘贴提取的蛋白质。

主要发现

  • 基于质谱的方法鉴定出银屑病角质层中140个差异表达蛋白质。
  • 表皮发育、糖酵解、凋亡调控、细胞骨架组织和肽交联等过程受到调节,反映表皮分化受扰。
  • 抗体技术观察到sICAM1水平升高,以及吸引中性粒细胞的CXCL1和CXCL8、吸引Th1细胞的CXCL10和CCL4、吸引单核细胞和树突状细胞的CCL2和CCL4水平升高。
  • 在皮损角质层中成功定量了Th1和Th17标志物TNF、IL12B、IL17A和IL17F,而未检测到不参与疾病过程的Th2细胞因子IL4、IL5和IL13。
  • 在皮损角质层中检测到瘙痒细胞因子IL31。

关键数值与推荐

  • 使用CXCL1、CXCL8、CXCL10和sICAM研究疾病缓解,根据已知临床疗效对三种局部治疗进行排序。

临床怎么用

  • 可利用银屑病角质层无创蛋白质组分析检测病理生理机制相关生物标志物。
  • CXCL1、CXCL8、CXCL10和sICAM等标志物可用于无创评估药物疗效和疾病缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protein expression is disturbed in the psoriatic stratum corneum (SC). Noninvasive methods for the description of pathophysiological changes and drug profiling in psoriasis are desirable. OBJECTIVES: Undertake large-scale noninvasive protein expression studies in psoriatic SC to identify biomarkers of pathophysiological processes and use them for drug profiling. METHODS: Psoriatic SC was harvested through repetitive tape-stripping. Nonlesional and lesional SC, as well as vehicle-treated and drug-treated lesional SC samples were collected. Protein extracts from nonlesional and lesional skin biopsies were used for comparison. Calcipotriol-betamethasone (CB) was used as a reference medication. Proteins extracted from pooled tape strips were quantified using mass spectrometry (MS), Western blotting, enzyme-linked immunosorbent assay and Luminex technologies. RESULTS: MS-based methods identified 140 proteins differentially expressed in psoriatic SC. Epidermis development, glycolysis, regulation of apoptosis, cytoskeleton organization and peptide cross-linking were modulated, all reflecting perturbed epidermal differentiation. Using antibody-based techniques, increased levels of sICAM1, of CXCL1- and CXCL8-attracting neutrophils, of CXCL10- and CCL4-attracting T helper (Th) 1 cells, and of CCL2- and CCL4-attracting monocytes and dendritic cells were observed. Quantification of the Th1 and Th17 markers tumour necrosis factor, interleukin (IL) 12B, IL17A and IL17F in lesional SC was successful, while the Th2 cytokines IL4, IL5 and IL13, not involved in the disease process, were not detected. The pruritic cytokine IL31 was detected in lesional SC. CXCL1, CXCL8, CXCL10 and sICAM were used to investigate disease remission, ranking three topical treatments according to their known clinical efficacy. CONCLUSIONS: Protein biomarker quantification in psoriatic SC detects key pathophysiological mechanisms and enables noninvasive drug profiling in translational medicine settings.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Méhul B, Laffet G, Séraïdaris A, et al. Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling. Br J Dermatol. 2017. PMID: 28129666. doi:10.1111/bjd.15346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。